Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Lilly Limerick is set to be the global pharmaceutical leader's most technically advanced manufacturing site to date ...

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a ...

Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

As grim as the likely loss of the U.K. market for the drug may be, Lilly is far from helpless, and the damage, while notable, might not actually drag on its growth by a noticeable amount if its ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, ...

The company's financial results should remain strong for a while. Analysts expect earnings per share (EPS) to grow at an ...

INDIANAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. "Lilly had another strong growth quarter in Q3, with ...